WebMD Health (WBMD) 10-Q 11 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	4-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	WBMD
Entity Registrant Name	WEBMD HEALTH CORP.
Entity Central Index Key	1326583
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		37,790,239

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$735,292	$706,776
Accounts receivable, net of allowance for doubtful accounts of $686 at March 31, 2015 and $631 at December 31, 2014	130,381	136,806
Prepaid expenses and other current assets	17,413	13,877
Deferred tax assets	18,453	18,147
Total current assets	901,539	875,606
Property and equipment, net	55,790	59,573
Goodwill	202,980	202,980
Intangible assets, net	13,382	14,215
Deferred tax assets	20,083	18,947
Other assets	26,509	26,236
TOTAL ASSETS	1,220,283	1,197,557
Current liabilities:
Accrued expenses	55,615	72,658
Deferred revenue	104,616	89,785
Total current liabilities	412,463	162,443
Other long-term liabilities	20,823	21,293
Commitments and contingencies
Stockholders' equity:
Preferred stock, 50,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.01 par value per share, 650,000,000 shares authorized; 57,437,992 shares issued at March 31, 2015 and December 31, 2014	574	574
Additional paid-in capital	9,223,602	9,214,800
Treasury stock, at cost; 20,872,817 shares at March 31, 2015 and 21,084,995 shares at December 31, 2014	-679,203	-685,659
Accumulated other comprehensive income	1,122	976
Accumulated deficit	-8,459,098	-8,469,102
Stockholders' equity	86,997	61,589
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	1,220,283	1,197,557
2.25% Convertible Notes Due 2016 [Member]
Current liabilities:
convertible notes current	252,232
Convertible notes		252,232
2.50% Convertible Notes Due 2018 [Member]
Current liabilities:
Convertible notes	400,000	400,000
1.50% Convertible Notes Due 2020 [Member]
Current liabilities:
Convertible notes	$300,000	$300,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance for doubtful accounts	$686	$631
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	650,000,000	650,000,000
Common stock, shares issued	57,437,992	57,437,992
Treasury stock, shares	20,872,817	21,084,995

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenue	$143,343	$133,832
Cost of operations	57,877	52,564
Sales and marketing	32,476	32,911
General and administrative	21,453	23,781
Depreciation and amortization	8,245	7,328
Interest income	17	15
Interest expense	6,172	6,172
Income before income tax provision	17,137	11,091
Income tax provision	7,133	4,825
Net income	$10,004	$6,266
Net income per common share:
Basic	$0.27	$0.16
Diluted	$0.25	$0.15
Weighted-average shares outstanding used in computing per share amounts:
Basic	36,393	39,268
Diluted	43,465	41,852

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income	$10,004	$6,266
Other comprehensive income, net of tax:
Net change in unrealized gains on available-for sale securities	146
Total other comprehensive income, net of tax	146
Comprehensive income	$10,150	$6,266

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income	$10,004	$6,266
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	8,245	7,328
Non-cash interest, net	1,128	1,128
Non-cash stock-based compensation	7,381	8,690
Deferred income taxes	-1,535	201
Changes in operating assets and liabilities:
Accounts receivable	6,425	-10,009
Prepaid expenses and other, net	-4,587	210
Accrued expenses and other long-term liabilities	-17,515	-20,401
Deferred revenue	14,831	14,490
Net cash provided by operating activities	24,377	7,903
Cash flows from investing activities:
Purchases of property and equipment	-3,670	-5,533
Net cash used in investing activities	-3,670	-5,533
Cash flows from financing activities:
Proceeds from exercise of stock options	4,488	17,482
Cash used for withholding taxes due on stock-based awards	-1,044	-5,326
Purchases of treasury stock	-3,219	-65,052
Excess tax benefit on stock-based awards	7,584	4,047
Net cash provided by (used in) financing activities	7,809	-48,849
Net increase (decrease) in cash and cash equivalents	28,516	-46,479
Cash and cash equivalents at beginning of period	706,776	824,880
Cash and cash equivalents at end of period	$735,292	$778,401

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1.    Summary of Significant Accounting Policies
	Background
	WebMD Health Corp. (the “Company” or “WebMD”) is a Delaware corporation that was incorporated on May 3, 2005. The Company completed an initial public offering on September 28, 2005. The Company’s Common Stock trades under the symbol “WBMD” on the Nasdaq Global Select Market. The Company generates revenue from the advertising and sponsorship services of The WebMD Health Network and related operations, from the private portal services it markets under the WebMD Health Services brand and from certain information services, each of which is described below and discussed further under “Presentation of Segment Information” in this Note 1.
	Advertising and Sponsorship. The WebMD Health Network includes: www.WebMD.com, the Company’s primary public portal for consumers and related mobile-optimized sites and mobile apps; www.Medscape.com, the Company’s primary public portal for physicians and other healthcare professionals and related mobile services; and other sites and apps through which the Company provides branded health and wellness content, tools and services. The Company’s services for consumers enable them to obtain information on health and wellness topics or on a particular disease or condition, to assess their personal health status, to use online trackers, tools and quizzes, to locate physicians, to receive periodic e-mailed newsletters and alerts on topics of individual interest, and to participate in online communities with peers and experts. The Company’s services for physicians and healthcare professionals make it easier for them to access clinical reference sources, stay abreast of the latest clinical information, learn about new treatment options, earn continuing medical education (“CME”) credit and communicate with peers. The Company does not charge any usage, membership or download fees for access to its public portals or mobile platforms. The Company generates revenue from its public portals and mobile platforms primarily through the sale of various types of advertising and sponsorship programs to its clients, which include: pharmaceutical, biotechnology and medical device companies; hospitals, clinics and other healthcare services companies; health insurance providers; consumer products companies whose products or services relate to health, wellness, diet, fitness, lifestyle, safety and illness prevention; and various other businesses, organizations and governmental entities. Advertisers and sponsors use the Company’s services to reach, educate and inform target audiences of consumers, physicians and other healthcare professionals. The Company also generates revenue from advertising sold in WebMD Magazine, a consumer magazine distributed to physician office waiting rooms.
	Private Portals Services. The Company’s private portals are a cloud-based population health management platform, hosted by the Company and provided to private and governmental employers and health plans for use by their employees and plan participants. The Company markets these private portals and related services under the WebMD Health Services brand. TheWebMD Health Services platform enables employers and health plans to provide their employees and plan participants with access to personalized health and benefit information, including an online personal health record application. The Company’s WebMD Health Services solutions include a comprehensive set of decision support and transparency tools that help their employees and plan participants understand the financial implications of their benefits options and make more informed benefits-related purchase decisions, and also provide access to information and services that can help them factor quality and cost into decisions about care and treatment options. The Company also provides telephonic, online and onsite health coaching and targeted condition management programs for use by its private portals clients’ employees and plan participants to help them make healthier lifestyle choices and achieve their wellness goals. The Company generates revenue from subscriptions to its WebMD Health Services platform by employers and health plans, either directly or through its distributors. WebMD offers its health coaching services and its condition management programs on a per-participant basis.
	Information Services. The Company also generates revenue from the sale of certain information products and services on a standalone basis using de-identified data that it licenses from a small number of third party data sources, of which the principal source is a license retained by HLTH Corporation, the Company’s former parent company, in connection with the sale of its Emdeon Business Services (EBS) business. As the successor to HLTH, the Company received this license which provides the Company the rights to certain de-identified data from the operation of the EBS business through February 2018 for use in the development and commercialization of various information products and services. Customers include data services, informatics and consulting companies.
	Interim Financial Statements
	The unaudited consolidated financial statements of the Company have been prepared by management and reflect all adjustments (consisting of only normal recurring adjustments) that, in the opinion of management, are necessary for a fair presentation of the interim periods presented. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results to be expected for any subsequent period or for the entire year ending December 31, 2015. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted under the Securities and Exchange Commission’s rules and regulations.
	The unaudited consolidated financial statements and notes included herein should be read in conjunction with the Company’s audited consolidated financial statements and notes for the year ended December 31, 2014, which are included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.
	Seasonality
	The timing of the Company’s revenue is affected by seasonal factors. The Company’s public portal advertising and sponsorship revenue is seasonal, primarily due to the annual spending patterns of the advertising and sponsorship clients of the Company’s public portals. This portion of the Company’s revenue is usually the lowest in the first quarter of each calendar year, and generally increases during each consecutive quarter throughout the year. The timing of revenue in relation to the Company’s expenses, many of which do not vary directly with revenue, has an impact on cost of operations, sales and marketing, and general and administrative expenses as a percentage of revenue in each calendar quarter.
	Accounting Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the Consolidated Financial Statements. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the amortization period of long-lived assets (excluding goodwill and indefinite-lived intangible assets), the carrying value, capitalization and amortization of software and Website development costs, the carrying value of investments, the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.
	Presentation of Segment Information
	The Company generates revenue in four groups, as set forth in the table below. The first group is “Advertising and Sponsorship — Biopharma and Medical Device” and consists of advertising and sponsorship revenue from pharmaceutical, biotechnology and medical device clients relating to ethical pharmaceutical products or other regulated devices or products or for sponsoring educational programs. The second category is “Advertising and Sponsorship — OTC, CPG and Other” and consists of advertising and sponsorship revenue relating to non-Rx or over-the-counter medications and other healthcare products, food and beverages, beauty products and other consumer products, as well as revenue from clients such as retailers, pharmacies, hospitals, health insurance companies and government agencies. The combined revenue of the first two groups is sometimes referred to as “Advertising and Sponsorship” revenue. The third group is “Private Portal Services” and consists of revenue from employers and health plans for subscriptions to the Company’s private portals solution and related services, including health coaching and condition management services. The fourth group is “Information Services” and consists of revenue from the sale of stand-alone information and data products. Discrete financial information related to a measure of profit or loss for these four revenue groups is not available as they leverage many common expenses, and the Company does not separately allocate these common expenses in assessing the performance of its business. Accordingly, the Company views its business as one reportable operating segment.
	The following table presents the revenues recognized from the four revenue groups described above during the three months ended March 31, 2015 and 2014:
		Three Months Ended
		March 31,
		2015		2014
	Advertising and sponsorship
	Biopharma and medical device	$	75,845	$	68,488
	OTC, CPG and other		29,948		34,469
			105,793		102,957
	Private portal services		29,322		24,629
	Information services		8,228		6,246
		$	143,343	$	133,832
	Loss Contingencies
	The Company accounts for loss contingencies in accordance with Financial Accounting Standards Board (“FASB”) ASC No. 450, “Contingencies.” Under ASC No. 450, accruals for loss contingencies are recorded when both (i) the information available indicates that it is probable that a liability has been incurred and (ii) the amount of the loss can be reasonably estimated. The Company records adjustments to these accruals to reflect the status of negotiations, settlements, advice of counsel and other information and events related to an individual matter.
	Net Income Per Common Share
	Basic income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods presented. Diluted income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods, increased to give effect to potentially dilutive securities and assumes that any dilutive convertible notes were converted, only in the periods in which such effect is dilutive (shares in thousands):
		Three Months Ended
		March 31,
		2015		2014
	Numerator:
	Net income — Basic	$	10,004	$	6,266
	Interest expense on 1.50% Notes, net of tax		864		—
	Net income — Diluted	$	10,868	$	6,266
	Denominator:
	Weighted-average shares — Basic		36,393		39,268
	Stock options and restricted stock		1,378		2,584
	1.50% Notes		5,694		—
	Adjusted weighted-average shares after assumed conversions — Diluted		43,465		41,852
	Net income per common share:
	Basic	$	0.27	$	0.16
	Diluted	$	0.25	$	0.15
	The Company has excluded certain of its convertible notes, as well as certain outstanding stock options and restricted stock, from the calculation of diluted income per common share during the periods in which such securities were anti-dilutive. The following table presents the total weighted-average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share during the periods presented (shares in thousands):
		Three Months Ended
		March 31,
		2015		2014
	Options and restricted stock		3,168		2,646
	1.50% Notes		—		5,681
	2.50% Notes		6,205		6,191
	2.25% Notes		3,511		3,503
			12,884		18,021
	Recent Accounting Pronouncements
	In April 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which changes the criteria for determining which disposals can be presented as discontinued operations and modifies the related disclosure requirements. Under the revised guidance, a discontinued operation is defined as a disposal of a component or group of components that represents a strategic shift that has, or will have, a major effect on an entity’s operations and financial results. The revised guidance is effective for the Company beginning in the quarter ended March 31, 2015. The adoption of the revised guidance did not have an impact on the Company’s consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under GAAP. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the revised guidance requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2017; early adoption is prohibited. The revised guidance is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. The Company has not yet determined the impact the revised guidance will have on its consolidated financial statements.
	In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2016; early adoption is permitted. The Company has not yet determined the impact the revised guidance will have on its consolidated financial statements.
	In April 2015, the FASB issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2016 and is required to be applied retrospectively. Early adoption is permitted. The Company has not yet determined the impact the revised guidance will have on its consolidated financial statements.
	In April 2015, the FASB issued ASU No. 2015-05, Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement, which provides guidance in determining whether a cloud computing arrangement includes a software license. If it is determined that a cloud computing arrangement does include a software license, the software element should be accounted for consistent with the acquisition of other software licenses. If the arrangement does not include a software license, it should be accounted for as a service contract. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2016 and can be applied prospectively to all arrangements entered into or materially modified after the effective date or retrospectively. Early adoption is permitted. The Company has not yet determined the impact the revised guidance will have on its consolidated financial statements.

Convertible_Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Convertible Notes	2.    Convertible Notes
	2.50% Convertible Notes due 2018
	On January 11, 2011, the Company issued $400,000 aggregate principal amount of its 2.50% Convertible Notes due 2018 (the “2.50% Notes”) in a private offering. Unless previously converted, the 2.50% Notes will mature on January 31, 2018. Net proceeds from the sale of the 2.50% Notes were approximately $387,345, after deducting the related offering expenses, of which approximately $100,000 was used to repurchase 1,920,490 shares of the Company’s Common Stock at a price of $52.07 per share, the last reported sale price of the Company’s Common Stock on January 5, 2011, which repurchase settled on January 11, 2011. Interest on the 2.50% Notes is payable semi-annually on January 31 and July 31 of each year, commencing July 31, 2011. Under the terms of the 2.50% Notes, holders were able to surrender their 2.50% Notes for conversion into the Company’s Common Stock at an initial conversion rate of 15.1220 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This was equivalent to an initial conversion price of approximately $66.13 per share of Common Stock. In the aggregate, the 2.50% Notes were convertible into 6,048,800 shares of the Company’s Common Stock.
	Effective April 4, 2012, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on April 3, 2012, the conversion rate was adjusted to 15.3223 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This was equivalent to an adjusted conversion price of approximately $65.26 per share of Common Stock. In the aggregate, the 2.50% Notes were convertible into 6,128,920 shares of Common Stock following the April 4, 2012 adjustment. Effective September 11, 2013, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on September 10, 2013, the conversion rate was adjusted to 15.4764 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This was equivalent to an adjusted conversion price of approximately $64.61 per share of Common Stock. In the aggregate, the 2.50% Notes were convertible into 6,190,560 shares of Common Stock following the September 11, 2013 adjustment.
	Effective September 10, 2014, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on September 9, 2014, the conversion rate was adjusted to 15.5118 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This is equivalent to an adjusted conversion price of approximately $64.47 per share of Common Stock. In the aggregate, the 2.50% Notes are convertible into 6,204,720 shares of Common Stock following the September 10, 2014 adjustment.
	Under the terms of the 2.50% Notes, if the Company undergoes certain change of control transactions prior to the maturity date of the 2.50% Notes, holders of the 2.50% Notes will have the right, at their option, to require the Company to repurchase some or all of their 2.50% Notes at a repurchase price equal to 100% of the principal amount of the 2.50% Notes being repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date. At the Company’s option, and to the extent permitted by the applicable rules of the Nasdaq Global Select Market (or the applicable rules of such other exchange on which the Company’s Common Stock may be listed), instead of paying the repurchase price in cash, the Company may pay the repurchase price in shares of its Common Stock or a combination of cash and shares of its Common Stock. However, in the case of certain change of control transactions in which the Company is acquired by a public company, the Company may elect to provide for conversion of the 2.50% Notes into acquirer common stock, in which case the repurchase option would not apply.
	2.25% Convertible Notes due 2016
	On March 14, 2011, the Company issued $400,000 aggregate principal amount of its 2.25% Convertible Notes due 2016 (the “2.25% Notes”) in a private offering. Unless previously converted, the 2.25% Notes will mature on March 31, 2016. Net proceeds from the sale of the 2.25% Notes were approximately $387,400, after deducting the related offering expenses, of which approximately $50,000 was used to repurchase 868,507 shares of the Company’s Common Stock at a price of $57.57 per share, the last reported sale price of the Company’s Common Stock on March 8, 2011, which repurchase settled on March 14, 2011. Interest on the 2.25% Notes is payable semi-annually on March 31 and September 30 of each year, commencing September 30, 2011. Under the terms of the 2.25% Notes, holders were able to surrender their 2.25% Notes for conversion into the Company’s Common Stock at an initial conversion rate of 13.5704 shares of Common Stock per thousand dollars principal amount of the 2.25% Notes. This was equivalent to an initial conversion price of approximately $73.69 per share of Common Stock. In the aggregate, the 2.25% Notes were convertible into 5,428,160 shares of the Company’s Common Stock.
	Effective April 4, 2012, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on April 3, 2012, the conversion rate was adjusted to 13.7502 shares of Common Stock per thousand dollars principal amount of the 2.25% Notes. This was equivalent to an adjusted conversion price of approximately $72.73 per share of Common Stock. In the aggregate, the 2.25% Notes were convertible into 5,500,080 shares of Common Stock following the April 4, 2012 adjustment. Effective September 11, 2013, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on September 10, 2013, the conversion rate was adjusted to 13.8884 shares of Common Stock per thousand dollars principal amount of the 2.25% Notes. This was equivalent to an adjusted conversion price of approximately $72.00 per share of Common Stock. In the aggregate, the 2.25% Notes were convertible into 5,555,360 shares of Common Stock following the September 11, 2013 adjustment.
	During the year ended December 31, 2013, the Company repurchased $100,000 principal amount of its 2.25% Notes for $101,750 in cash in a privately negotiated transaction. Also during the year ended December 31, 2013, the Company repurchased $47,768 principal amount of its 2.25% Notes for $48,604 in cash in the open market. The Company recognized a pre-tax loss of $4,871 in 2013 related to these repurchases. The loss included the expensing of the remaining deferred issuance costs outstanding related to the repurchased notes. After these repurchases in 2013, the remaining principal amount of the 2.25% Notes outstanding was $252,232, which, in the aggregate, was convertible into 3,503,099 shares of Common Stock.
	Effective September 10, 2014, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on September 9, 2014, the conversion rate was adjusted to 13.9202 shares of Common Stock per thousand dollars principal amount of the 2.25% Notes. This is equivalent to an adjusted conversion price of approximately $71.84 per share of Common Stock. In the aggregate, the 2.25% Notes are convertible into 3,511,120 shares of Common Stock following the September 10, 2014 adjustment.
	Under the terms of the 2.25% Notes, if the Company undergoes certain change of control transactions prior to the maturity date of the 2.25% Notes, holders of the 2.25% Notes will have the right, at their option, to require the Company to repurchase some or all of their 2.25% Notes at a repurchase price equal to 100% of the principal amount of the 2.25% Notes being repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date. At the Company’s option, and to the extent permitted by the applicable rules of the Nasdaq Global Select Market (or the applicable rules of such other exchange on which the Company’s Common Stock may be listed), instead of paying the repurchase price in cash, the Company may pay the repurchase price in shares of its Common Stock or a combination of cash and shares of its Common Stock. However, in the case of certain change of control transactions in which the Company is acquired by a public company, the Company may elect to provide for conversion of the 2.25% Notes into acquirer common stock, in which case the repurchase option would not apply.
	1.50% Convertible Notes due 2020
	On November 26, 2013, the Company issued $300,000 aggregate principal amount of its 1.50% Convertible Notes due 2020 (the “1.50% Notes”) in a private offering. Unless previously converted, the 1.50% Notes will mature on December 1, 2020. Net proceeds from the sale of the 1.50% Notes were approximately $291,823, after deducting the related offering expenses. Interest on the 1.50% Notes is payable semi-annually on June 1 and December 1 of each year, commencing June 1, 2014. Under the terms of the 1.50% Notes, holders were able to surrender their 1.50% Notes for conversion into the Company’s Common Stock at an initial conversion rate of 18.9362 shares of Common Stock per thousand dollars principal amount of the 1.50% Notes. This was equivalent to an initial conversion price of approximately $52.81 per share of Common Stock. In the aggregate, the 1.50% Notes were convertible into 5,680,860 shares of the Company’s Common Stock. The conversion rate may be adjusted under certain circumstances.
	Effective September 10, 2014, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on September 9, 2014, the conversion rate was adjusted to 18.9795 shares of Common Stock per thousand dollars principal amount of the 1.50% Notes. This is equivalent to an adjusted conversion price of approximately $52.69 per share of Common Stock. In the aggregate, the 1.50% Notes are convertible into 5,693,850 shares of Common Stock following the September 10, 2014 adjustment.
	Under the terms of the 1.50% Notes, if the Company undergoes certain change of control or other fundamental change transactions prior to the maturity date of the 1.50% Notes, holders of the 1.50% Notes will have the right, at their option, to require the Company to repurchase some or all of their 1.50% Notes at a repurchase price equal to 100% of the principal amount of the 1.50% Notes being repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date. However, the repurchase option will not apply in the case of certain change of control or other fundamental change transactions in which the Company is acquired by a public company, and (a) not less than 90% of the consideration received or to be received by holders of WebMD Common Stock, excluding cash payments for fractional shares, consists of acquirer common stock and (b) as a result of the transaction, the 1.50% Notes become convertible into the same consideration.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	3.    Fair Value of Financial Instruments
	The Company accounts for certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, the Company uses valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:
	Level 1:	Observable inputs such as quoted market prices in active markets for identical assets or liabilities.
	Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data.
	Level 3:	Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.
	The Company did not have any Level 2 or Level 3 assets during the periods presented. The following table sets forth the Company’s Level 1 financial assets that were measured and recorded at fair value on a recurring basis as of March 31, 2015 and December 31, 2014:
				March 31, 2015						December 31, 2014
		Fair Value		Amortized		Fair Value		Gross		Amortized		Fair Value		Gross
		Estimate		Cost Basis				Unrealized		Cost Basis				Unrealized
		Using:						Gains						Gains
	Cash and cash equivalents		Level 1	$	735,292	$	735,292	$	—	$	706,776	$	706,776	$	—
	Available-for-sale security		Level 1		—		1,842		1,842		—		1,603		1,603
	The Company’s available-for-sale security consists of an equity investment in a publicly traded company that completed its initial public offering in December 2014. The unrealized gain related to this investment, net of tax, is included within accumulated other comprehensive income in the accompanying consolidated balance sheets as of March 31, 2015 and December 31, 2014.
	The Company also holds an investment in a privately held company which is carried at cost, and not subject to fair value measurements. However, if events or circumstances indicate that its carrying amount may not be recoverable, it would be reviewed for impairment. The Company made this investment in November 2008 by acquiring preferred stock. During November 2014, this investment was converted into a combination of preferred stock and debt securities of another privately held company through an acquisition. The total amount of the Company’s investment in this privately held company is $6,471, which includes $470 of acquisition costs. Since the Company does not have the ability to exercise significant influence over this company, the investment is accounted for under the cost method and it is included in other assets on the accompanying consolidated balance sheets as of March 31, 2015 and December 31, 2014.
	For disclosure purposes, the Company is required to measure the outstanding value of its debt on a recurring basis. The following table presents the carrying value and estimated fair value (based on Level 1 market price data) of the Company’s convertible notes that were carried at historical cost as of March 31, 2015 and December 31, 2014:
		March 31, 2015				December 31, 2014
		Carrying Amount		Fair Value		Carrying Amount		Fair Value
	2.25% Notes	$	252,232	$	253,493	$	252,232	$	254,754
	2.50% Notes	$	400,000	$	409,000	$	400,000	$	399,000
	1.50% Notes	$	300,000	$	321,000	$	300,000	$	299,250

Equity

Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Equity	4.    Equity
	Stock Repurchase Program
	In August 2011, the Board of Directors established a stock repurchase program (the “Program”) through which the Company was authorized to use up to $75,000 to purchase shares of WebMD Common Stock, from time to time, in the open market through block trades or in private transactions, depending on market conditions and other factors. In October 2011, February 2014, March 2014, April 2014 and November 2014, the Company’s Board of Directors authorized increases to the Program of $75,000, $50,000, $40,000, $30,000 and $23,895, respectively. During the three months ended March 31, 2015, the Company repurchased 83,504 shares at an aggregate cost of $3,219 under the Program. During the three months ended March 31, 2014, the Company repurchased 1,594,904 shares at an aggregate cost of $67,506 under the Program, of which 60,049 shares at an aggregate cost of $2,454 were repurchased at the end of March 2014 and did not settle until April 2014. As of March 31, 2015, $31,792 remained available for repurchases under the Program.
	Accumulated Other Comprehensive Income
	Accumulated other comprehensive income in the accompanying consolidated balance sheets as of March 31, 2015 and December 31, 2014 represents the unrealized gain on available-for-sale securities, net of taxes (see Note 3 for additional discussion).

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5.    Intangible Assets
	Intangible assets consist of the following:
			March 31, 2015									December 31, 2014
			Gross		Accumulated			Net		Weighted		Gross		Accumulated			Net		Weighted
			Carrying		Amortization					Average		Carrying		Amortization					Average
			Amount							Remaining		Amount							Remaining
										Useful Life (a)									Useful Life (a)
	Content		$	15,954	$	(15,954	)	$	—		—	$	15,954	$	(15,954	)	$	—		—
	Customer relationships			34,057		(27,650	)		6,407		3.3		34,057		(27,126	)		6,931		3.6
	Technology and patents			17,882		(15,498	)		2,384		2.3		17,882		(15,231	)		2,651		2.5
	Trade names-definite lives			2,530		(2,403	)		127		0.7		2,530		(2,361	)		169		1
	Trade names-indefinite lives			4,464		—			4,464		n/a		4,464		—			4,464		n/a
	Total		$	74,887	$	(61,505	)	$	13,382			$	74,887	$	(60,672	)	$	14,215
	(a)	The calculation of the weighted-average remaining useful life is based on the net book value and the remaining amortization period of each respective intangible asset.
	Amortization expense was $833 and $568 during the three months ended March 31, 2015 and 2014, respectively. Aggregate amortization expense for intangible assets is estimated to be:
	Year Ending December 31:
	2015 (April 1st to December 31st)		$	2,488
	2016		$	3,120
	2017		$	2,044
	2018		$	1,266

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6.    Commitments and Contingencies
	Legal Proceedings
	National Jewish Health v. WebMD Health Services Group, Inc. and WebMD Health Corp.
	On October 25, 2012, National Jewish Health, a Colorado non-profit corporation, filed a complaint against the Company in United States District Court for the District of Colorado alleging copyright infringement, misappropriation of trade secrets, tortious interference with prospective business relations, and breach of contract. The allegations related to a condition management program of the Company’s private portals. The complaint sought injunctive relief, as well as monetary damages. On January 28, 2015, the parties entered into a Settlement Agreement pursuant to which, on February 20, 2015, the parties filed with the Court a Joint Motion to Dismiss all claims with prejudice. Neither party has admitted any liability to the other and the Company’s private portals business is not required to modify, suspend or terminate the sale of any of its products.
	MyMedicalRecords, Inc. v. WebMD Health Corp. and WebMD Health Services Corp.
	On February 13, 2013, MyMedicalRecords, Inc. filed an action against the Company in the United States District Court in the Central District of California. The complaint alleged that the personal health record tool sold by WebMD Health Services Group, Inc. infringes U.S. Patent No. 8,301,466 issued on October 30, 2012. The complaint sought injunctive relief, as well as damages in unspecified amounts. Pursuant to an agreement between the parties, MyMedicalRecords dismissed the complaint without prejudice in order to enable the parties to try to resolve the matter without the timing constraints of the litigation. The parties were unable to resolve the matter and, on October 2, 2013, MyMedicalRecords filed a new complaint against the Company alleging infringement of U.S. Patent No. 8,301,466 as well as U.S. Patent No. 8,498,883 issued on July 30, 2013. The Plaintiff sought unspecified damages and an injunction with respect to certain products offered by the Company. The Court had consolidated the Plaintiff’s claim against the Company with its claims against several other companies. On December 22, 2014, the Court granted summary judgment in favor of the Company and its co-defendants finding that the ‘883 patent is invalid. On December 23, 2014, the Court granted summary judgment in favor of the Company and its co-defendants finding that the ‘466 patent is invalid. On January 6, 2015, the Court entered a final order dismissing the case. On January 15, 2015, MyMedicalRecords filed a Notice of Appeal of the Court’s order with the Circuit Court for the Federal Circuit. If the Court’s order is appealed, the Company plans to defend the Order of the District Court. The Company is unable to predict the outcome of any appeal or to reasonably estimate the possible loss or range of loss, if any, arising from the claims that may be asserted therein.
	Coverage Dispute with Stop Loss Carrier for Health Benefit Plan
	On June 27, 2013, the Company filed an action in the Supreme Court, State of New York (“New York Action”), seeking payment from Everest Reinsurance Company (“Everest”) of $1,965 in outstanding claims under a stop loss insurance policy issued by Everest for certain medical claims under the Company’s self-insured group health and prescription benefit plan (the “Health Plan”) for its eligible employees and their dependents that were pending under the 2012 stop loss policy. On December 9, 2013, Everest answered the New York Action complaint and filed a counterclaim against the Company, the claims administrator under the Health Plan and the Company’s insurance broker seeking recovery of approximately $2,935 paid by Everest under the 2011 and 2012 stop loss policies and seeking a declaration that the remaining $1,965 was not payable by Everest. On April 27, 2015, the parties entered into a binding settlement term sheet, and formal documentation is now being negotiated, after which the parties will file a stipulation of discontinuance of all claims by all parties. As a result of the settlement, substantially all of the amount due from Everest will be recoverable and the $2,935 previously paid by Everest will not be repayable by the Company.
	Traffic Information, LLC v. WebMD LLC
	On June 25, 2014, Traffic Information, LLC filed an action against the Company in the United States District Court in the Eastern District of Texas. The complaint alleges that the Company directly infringes and has induced infringement of U.S. Patent No. 6,785,606 issued on August 31, 2004. The parties entered into a settlement agreement pursuant to which, on April 21, 2015, the parties filed a joint stipulation for dismissal of the action which is pending action by the Court. Under the terms of the agreement, neither party has admitted any liability to the other and the Company is not required to modify, suspend or terminate the sale of any of its products.
	Patent Claim by International Business Machines Corporation
	In February 2015, International Business Machines Corporation (“IBM”) notified the Company that IBM believes that the Company’s Websites infringe U.S. Patents 7,072,849, 5,796,967 and 6,374,359. The Company has had discussions with IBM regarding those allegations. The Company believes that it is not infringing any intellectual property rights of IBM. The Company is continuing to evaluate IBM’s allegations and is considering its alternatives regarding this matter.
	Other Legal Proceedings
	In the normal course of business, the Company and its subsidiaries are involved in various claims and legal proceedings. While the ultimate resolution of these matters, including those discussed in Note 7 to the Consolidated Financial Statements included in the Company’s 2014 Annual Report on Form 10-K, has yet to be determined, the Company does not believe that their outcomes will have a material adverse effect on the Company’s consolidated financial position, results of operations or liquidity.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	7.    Stock-Based Compensation
	The Company has various stock-based compensation plans (collectively, the “Plans”) that provide for the grant of stock options, restricted stock, and other awards based on WebMD Common Stock.
	The 2005 Long-Term Incentive Plan (as amended, the “2005 Plan”) is the only existing plan under which future grants can be made. The maximum number of shares of the Company’s Common Stock that may be subject to awards under the 2005 Plan was 23,275,000 as of March 31, 2015, subject to adjustment in accordance with the terms of the 2005 Plan. The Company had an aggregate of 354,049 shares of Common Stock available for future grants under the 2005 Plan at March 31, 2015.
	Stock Options
	Generally, options under the Plans vest and become exercisable ratably over periods ranging from two to five years based on their individual grant dates, subject to continued employment on the applicable vesting dates, and generally expire within ten years from the date of grant. Options are granted at prices not less than the fair market value of the Company’s Common Stock on the date of grant. The following table summarizes stock option activity for the Plans:
			Shares			Weighted		Weighted		Aggregate
						Average Exercise		Average		Intrinsic Value (a)
						Price Per Share		Remaining
								Contractual
								Life (In Years)
	Outstanding at January 1, 2015			7,547,526		$	32.69
	Granted			1,678,500			42.52
	Exercised			(313,663	)		18.44
	Cancelled			(137,075	)		29.9
	Outstanding at March 31, 2015			8,775,288		$	35.12		7.3	$	81,634
	Vested and exercisable at the end of the period			3,561,862		$	31.08		5	$	49,189
	(a)	The aggregate intrinsic value is based on the market price of the Company’s Common Stock on March 31, 2015, which was $43.835, less the applicable exercise price of the underlying option. This aggregate intrinsic value represents the amount that would have been realized if all the option holders had exercised their options on March 31, 2015.
	The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model considering the weighted-average assumptions noted in the following table. Expected volatility is based on implied volatility from traded options of the Company’s Common Stock combined with historical volatility of the Company’s Common Stock. The expected term represents the period of time that options are expected to be outstanding following their grant date, and was determined using historical exercise data combined with assumptions for future exercise activity. The risk-free rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date.
			Three Months Ended
			March 31,
			2015			2014
	Expected dividend yield			0.00%			0.00%
	Expected volatility			0.46 - 0.48			0.48 - 0.49
	Risk-free interest rate			1.01% - 1.56%			1.28% - 1.71%
	Expected term (years)			4.1 - 4.7			4.3 - 4.9
	Weighted-average fair value of options granted during the period		$	16.34		$	17.47
	Restricted Stock
	The Company’s Restricted Stock consists of shares of the Company’s Common Stock which have been awarded to employees with restrictions that cause them to be subject to substantial risk of forfeiture and restrict their sale or other transfer by the employee until they vest. Generally, the Company’s Restricted Stock grants vest ratably over periods ranging from three to four years from their individual award dates subject to continued employment on the applicable vesting dates. The following table summarizes the activity of the Company’s Restricted Stock:
			Shares			Weighted
						Average Grant
						Date Fair Value
	Balance at January 1, 2015			904,083		$	35.58
	Granted			355,920			42.75
	Vested			(34,216	)		46.43
	Forfeited			(25,000	)		26.22
	Balance at March 31, 2015			1,200,787		$	37.6
	Proceeds received from the exercise of options to purchase shares of the Company’s Common Stock were $4,488 and $17,482 during the three months ended March 31, 2015 and 2014, respectively. Additionally, in connection with the exercise of certain stock options and the vesting of restricted stock, the Company made payments of $1,044 and $5,326 during the three months ended March 31, 2015 and 2014, respectively, related to employee statutory withholding taxes that were satisfied by withholding shares of Common Stock of equal value from the respective employees. The proceeds and payments described above are reflected within cash flows from financing activities within the accompanying consolidated statements of cash flows.
	The intrinsic value related to stock options that were exercised, combined with the fair value of shares of restricted stock that vested, aggregated $9,135 and $25,983 for the three months ended March 31, 2015 and 2014, respectively.
	Other
	Each year, the Company issues shares of its Common Stock to WebMD non-employee directors with a value equal to their annual board and committee retainers. The Company recorded $117 and $77 of stock-based compensation expense for the three months ended March 31, 2015 and 2014, respectively, in connection with these issuances.
	Summary of Stock-Based Compensation Expense
	The following table summarizes the components and classification of stock-based compensation expense:
			Three Months Ended
			March 31,
			2015			2014
	Stock options		$	4,660		$	5,466
	Restricted stock			2,604			3,147
	Other			117			77
	Total stock-based compensation expense		$	7,381		$	8,690
	Included in:
	Cost of operations		$	1,389		$	1,464
	Sales and marketing			1,448			2,105
	General and administrative			4,544			5,121
	Total stock-based compensation expense		$	7,381		$	8,690
	As of March 31, 2015, approximately $81,620 of unrecognized stock-based compensation expense related to unvested awards (net of estimated forfeitures) is expected to be recognized over a weighted-average period of approximately 2.8 years, related to the Plans.
	Tax benefits attributable to stock-based compensation represented 38% and 39% of stock-based compensation expense for the three months ended March 31, 2015 and 2014, respectively.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Background	Background
	WebMD Health Corp. (the “Company” or “WebMD”) is a Delaware corporation that was incorporated on May 3, 2005. The Company completed an initial public offering on September 28, 2005. The Company’s Common Stock trades under the symbol “WBMD” on the Nasdaq Global Select Market. The Company generates revenue from the advertising and sponsorship services of The WebMD Health Network and related operations, from the private portal services it markets under the WebMD Health Services brand and from certain information services, each of which is described below and discussed further under “Presentation of Segment Information” in this Note 1.
	Advertising and Sponsorship. The WebMD Health Network includes: www.WebMD.com, the Company’s primary public portal for consumers and related mobile-optimized sites and mobile apps; www.Medscape.com, the Company’s primary public portal for physicians and other healthcare professionals and related mobile services; and other sites and apps through which the Company provides branded health and wellness content, tools and services. The Company’s services for consumers enable them to obtain information on health and wellness topics or on a particular disease or condition, to assess their personal health status, to use online trackers, tools and quizzes, to locate physicians, to receive periodic e-mailed newsletters and alerts on topics of individual interest, and to participate in online communities with peers and experts. The Company’s services for physicians and healthcare professionals make it easier for them to access clinical reference sources, stay abreast of the latest clinical information, learn about new treatment options, earn continuing medical education (“CME”) credit and communicate with peers. The Company does not charge any usage, membership or download fees for access to its public portals or mobile platforms. The Company generates revenue from its public portals and mobile platforms primarily through the sale of various types of advertising and sponsorship programs to its clients, which include: pharmaceutical, biotechnology and medical device companies; hospitals, clinics and other healthcare services companies; health insurance providers; consumer products companies whose products or services relate to health, wellness, diet, fitness, lifestyle, safety and illness prevention; and various other businesses, organizations and governmental entities. Advertisers and sponsors use the Company’s services to reach, educate and inform target audiences of consumers, physicians and other healthcare professionals. The Company also generates revenue from advertising sold in WebMD Magazine, a consumer magazine distributed to physician office waiting rooms.
	Private Portals Services. The Company’s private portals are a cloud-based population health management platform, hosted by the Company and provided to private and governmental employers and health plans for use by their employees and plan participants. The Company markets these private portals and related services under the WebMD Health Services brand. The WebMD Health Services platform enables employers and health plans to provide their employees and plan participants with access to personalized health and benefit information, including an online personal health record application. The Company’s WebMD Health Services solutions include a comprehensive set of decision support and transparency tools that help their employees and plan participants understand the financial implications of their benefits options and make more informed benefits-related purchase decisions, and also provide access to information and services that can help them factor quality and cost into decisions about care and treatment options. The Company also provides telephonic, online and onsite health coaching and targeted condition management programs for use by its private portals clients’ employees and plan participants to help them make healthier lifestyle choices and achieve their wellness goals. The Company generates revenue from subscriptions to its WebMD Health Services platform by employers and health plans, either directly or through its distributors. WebMD offers its health coaching services and its condition management programs on a per-participant basis.
	Information Services. The Company also generates revenue from the sale of certain information products and services on a standalone basis using de-identified data that it licenses from a small number of third party data sources, of which the principal source is a license retained by HLTH Corporation, the Company’s former parent company, in connection with the sale of its Emdeon Business Services (EBS) business. As the successor to HLTH, the Company received this license which provides the Company the rights to certain de-identified data from the operation of the EBS business through February 2018 for use in the development and commercialization of various information products and services. Customers include data services, informatics and consulting companies.
Interim Financial Statements	Interim Financial Statements
	The unaudited consolidated financial statements of the Company have been prepared by management and reflect all adjustments (consisting of only normal recurring adjustments) that, in the opinion of management, are necessary for a fair presentation of the interim periods presented. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results to be expected for any subsequent period or for the entire year ending December 31, 2015. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted under the Securities and Exchange Commission’s rules and regulations.
	The unaudited consolidated financial statements and notes included herein should be read in conjunction with the Company’s audited consolidated financial statements and notes for the year ended December 31, 2014, which are included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Seasonality	Seasonality
	The timing of the Company’s revenue is affected by seasonal factors. The Company’s public portal advertising and sponsorship revenue is seasonal, primarily due to the annual spending patterns of the advertising and sponsorship clients of the Company’s public portals. This portion of the Company’s revenue is usually the lowest in the first quarter of each calendar year, and generally increases during each consecutive quarter throughout the year. The timing of revenue in relation to the Company’s expenses, many of which do not vary directly with revenue, has an impact on cost of operations, sales and marketing, and general and administrative expenses as a percentage of revenue in each calendar quarter.
Accounting Estimates	Accounting Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the Consolidated Financial Statements. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the amortization period of long-lived assets (excluding goodwill and indefinite-lived intangible assets), the carrying value, capitalization and amortization of software and Website development costs, the carrying value of investments, the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.
Presentation of Segment Information	Presentation of Segment Information
	The Company generates revenue in four groups, as set forth in the table below. The first group is “Advertising and Sponsorship — Biopharma and Medical Device” and consists of advertising and sponsorship revenue from pharmaceutical, biotechnology and medical device clients relating to ethical pharmaceutical products or other regulated devices or products or for sponsoring educational programs. The second category is “Advertising and Sponsorship — OTC, CPG and Other” and consists of advertising and sponsorship revenue relating to non-Rx or over-the-counter medications and other healthcare products, food and beverages, beauty products and other consumer products, as well as revenue from clients such as retailers, pharmacies, hospitals, health insurance companies and government agencies. The combined revenue of the first two groups is sometimes referred to as “Advertising and Sponsorship” revenue. The third group is “Private Portal Services” and consists of revenue from employers and health plans for subscriptions to the Company’s private portals solution and related services, including health coaching and condition management services. The fourth group is “Information Services” and consists of revenue from the sale of stand-alone information and data products. Discrete financial information related to a measure of profit or loss for these four revenue groups is not available as they leverage many common expenses, and the Company does not separately allocate these common expenses in assessing the performance of its business. Accordingly, the Company views its business as one reportable operating segment.
	The following table presents the revenues recognized from the four revenue groups described above during the three months ended March 31, 2015 and 2014:
		Three Months Ended
		March 31,
		2015		2014
	Advertising and sponsorship
	Biopharma and medical device	$	75,845	$	68,488
	OTC, CPG and other		29,948		34,469
			105,793		102,957
	Private portal services		29,322		24,629
	Information services		8,228		6,246
		$	143,343	$	133,832
Loss Contingencies	Loss Contingencies
	The Company accounts for loss contingencies in accordance with Financial Accounting Standards Board (“FASB”) ASC No. 450, “Contingencies.” Under ASC No. 450, accruals for loss contingencies are recorded when both (i) the information available indicates that it is probable that a liability has been incurred and (ii) the amount of the loss can be reasonably estimated. The Company records adjustments to these accruals to reflect the status of negotiations, settlements, advice of counsel and other information and events related to an individual matter.
Net Income Per Common Share	Net Income Per Common Share
	Basic income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods presented. Diluted income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods, increased to give effect to potentially dilutive securities and assumes that any dilutive convertible notes were converted, only in the periods in which such effect is dilutive (shares in thousands):
		Three Months Ended
		March 31,
		2015		2014
	Numerator:
	Net income — Basic	$	10,004	$	6,266
	Interest expense on 1.50% Notes, net of tax		864		—
	Net income — Diluted	$	10,868	$	6,266
	Denominator:
	Weighted-average shares — Basic		36,393		39,268
	Stock options and restricted stock		1,378		2,584
	1.50% Notes		5,694		—
	Adjusted weighted-average shares after assumed conversions — Diluted		43,465		41,852
	Net income per common share:
	Basic	$	0.27	$	0.16
	Diluted	$	0.25	$	0.15
	The Company has excluded certain of its convertible notes, as well as certain outstanding stock options and restricted stock, from the calculation of diluted income per common share during the periods in which such securities were anti-dilutive. The following table presents the total weighted-average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share during the periods presented (shares in thousands):
		Three Months Ended
		March 31,
		2015		2014
	Options and restricted stock		3,168		2,646
	1.50% Notes		—		5,681
	2.50% Notes		6,205		6,191
	2.25% Notes		3,511		3,503
			12,884		18,021
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In April 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which changes the criteria for determining which disposals can be presented as discontinued operations and modifies the related disclosure requirements. Under the revised guidance, a discontinued operation is defined as a disposal of a component or group of components that represents a strategic shift that has, or will have, a major effect on an entity’s operations and financial results. The revised guidance is effective for the Company beginning in the quarter ended March 31, 2015. The adoption of the revised guidance did not have an impact on the Company’s consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under GAAP. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the revised guidance requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2017; early adoption is prohibited. The revised guidance is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. The Company has not yet determined the impact the revised guidance will have on its consolidated financial statements.
	In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2016; early adoption is permitted. The Company has not yet determined the impact the revised guidance will have on its consolidated financial statements.
	In April 2015, the FASB issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2016 and is required to be applied retrospectively. Early adoption is permitted. The Company has not yet determined the impact the revised guidance will have on its consolidated financial statements.
	In April 2015, the FASB issued ASU No. 2015-05, Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement, which provides guidance in determining whether a cloud computing arrangement includes a software license. If it is determined that a cloud computing arrangement does include a software license, the software element should be accounted for consistent with the acquisition of other software licenses. If the arrangement does not include a software license, it should be accounted for as a service contract. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2016 and can be applied prospectively to all arrangements entered into or materially modified after the effective date or retrospectively. Early adoption is permitted. The Company has not yet determined the impact the revised guidance will have on its consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Revenues from Four Revenue Groups	The following table presents the revenues recognized from the four revenue groups described above during the three months ended March 31, 2015 and 2014:
		Three Months Ended
		March 31,
		2015		2014
	Advertising and sponsorship
	Biopharma and medical device	$	75,845	$	68,488
	OTC, CPG and other		29,948		34,469
			105,793		102,957
	Private portal services		29,322		24,629
	Information services		8,228		6,246
		$	143,343	$	133,832
Schedule of Net Income Per Common Shares	Basic income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods presented. Diluted income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods, increased to give effect to potentially dilutive securities and assumes that any dilutive convertible notes were converted, only in the periods in which such effect is dilutive (shares in thousands):
		Three Months Ended
		March 31,
		2015		2014
	Numerator:
	Net income — Basic	$	10,004	$	6,266
	Interest expense on 1.50% Notes, net of tax		864		—
	Net income — Diluted	$	10,868	$	6,266
	Denominator:
	Weighted-average shares — Basic		36,393		39,268
	Stock options and restricted stock		1,378		2,584
	1.50% Notes		5,694		—
	Adjusted weighted-average shares after assumed conversions — Diluted		43,465		41,852
	Net income per common share:
	Basic	$	0.27	$	0.16
	Diluted	$	0.25	$	0.15
Weighted Average Number of Potentially Dilutive Common Shares Excluded from Computation of Diluted Income Per Common Share	The Company has excluded certain of its convertible notes, as well as certain outstanding stock options and restricted stock, from the calculation of diluted income per common share during the periods in which such securities were anti-dilutive. The following table presents the total weighted-average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share during the periods presented (shares in thousands):
		Three Months Ended
		March 31,
		2015		2014
	Options and restricted stock		3,168		2,646
	1.50% Notes		—		5,681
	2.50% Notes		6,205		6,191
	2.25% Notes		3,511		3,503
			12,884		18,021

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Financial Assets Measured and Recorded at Fair Value on Recurring Basis	The following table sets forth the Company’s Level 1 financial assets that were measured and recorded at fair value on a recurring basis as of March 31, 2015 and December 31, 2014:
				March 31, 2015						December 31, 2014
		Fair Value		Amortized		Fair Value		Gross		Amortized		Fair Value		Gross
		Estimate		Cost Basis				Unrealized		Cost Basis				Unrealized
		Using:						Gains						Gains
	Cash and cash equivalents		Level 1	$	735,292	$	735,292	$	—	$	706,776	$	706,776	$	—
	Available-for-sale security		Level 1		—		1,842		1,842		—		1,603		1,603
Carrying Value and Estimated Fair Value of Company's Convertible Notes that are Carried at Historical Cost	The following table presents the carrying value and estimated fair value (based on Level 1 market price data) of the Company’s convertible notes that were carried at historical cost as of March 31, 2015 and December 31, 2014:
		March 31, 2015				December 31, 2014
		Carrying Amount		Fair Value		Carrying Amount		Fair Value
	2.25% Notes	$	252,232	$	253,493	$	252,232	$	254,754
	2.50% Notes	$	400,000	$	409,000	$	400,000	$	399,000
	1.50% Notes	$	300,000	$	321,000	$	300,000	$	299,250

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite and Indefinite Lived Intangible Assets	Intangible assets consist of the following:
			March 31, 2015									December 31, 2014
			Gross		Accumulated			Net		Weighted		Gross		Accumulated			Net		Weighted
			Carrying		Amortization					Average		Carrying		Amortization					Average
			Amount							Remaining		Amount							Remaining
										Useful Life (a)									Useful Life (a)
	Content		$	15,954	$	(15,954	)	$	—		—	$	15,954	$	(15,954	)	$	—		—
	Customer relationships			34,057		(27,650	)		6,407		3.3		34,057		(27,126	)		6,931		3.6
	Technology and patents			17,882		(15,498	)		2,384		2.3		17,882		(15,231	)		2,651		2.5
	Trade names-definite lives			2,530		(2,403	)		127		0.7		2,530		(2,361	)		169		1
	Trade names-indefinite lives			4,464		—			4,464		n/a		4,464		—			4,464		n/a
	Total		$	74,887	$	(61,505	)	$	13,382			$	74,887	$	(60,672	)	$	14,215
	(a)	The calculation of the weighted-average remaining useful life is based on the net book value and the remaining amortization period of each respective intangible asset.
Amortization Expense for Intangible Assets	Aggregate amortization expense for intangible assets is estimated to be:
	Year Ending December 31:
	2015 April 1st to December 31st)		$	2,488
	2016		$	3,120
	2017		$	2,044
	2018		$	1,266

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-Based Compensation, Stock Options, Activity	The following table summarizes stock option activity for the Plans:
			Shares			Weighted		Weighted		Aggregate
						Average Exercise		Average		Intrinsic Value (a)
						Price Per Share		Remaining
								Contractual
								Life (In Years)
	Outstanding at January 1, 2015			7,547,526		$	32.69
	Granted			1,678,500			42.52
	Exercised			(313,663	)		18.44
	Cancelled			(137,075	)		29.9
	Outstanding at March 31, 2015			8,775,288		$	35.12		7.3	$	81,634
	Vested and exercisable at the end of the period			3,561,862		$	31.08		5	$	49,189
	(a)	The aggregate intrinsic value is based on the market price of the Company’s Common Stock on March 31, 2015, which was $43.835, less the applicable exercise price of the underlying option. This aggregate intrinsic value represents the amount that would have been realized if all the option holders had exercised their options on March 31, 2015.
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The risk-free rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date.
			Three Months Ended
			March 31,
			2015			2014
	Expected dividend yield			0.00%			0.00%
	Expected volatility			0.46 - 0.48			0.48 - 0.49
	Risk-free interest rate			1.01% - 1.56%			1.28% - 1.71%
	Expected term (years)			4.1 - 4.7			4.3 - 4.9
	Weighted-average fair value of options granted during the period		$	16.34		$	17.47
Schedule of Share-based Compensation, Restricted Stock Awards, Activity	The following table summarizes the activity of the Company’s Restricted Stock:
			Shares			Weighted
						Average Grant
						Date Fair Value
	Balance at January 1, 2015			904,083		$	35.58
	Granted			355,920			42.75
	Vested			(34,216	)		46.43
	Forfeited			(25,000	)		26.22
	Balance at March 31, 2015			1,200,787		$	37.6
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The following table summarizes the components and classification of stock-based compensation expense:
			Three Months Ended
			March 31,
			2015			2014
	Stock options		$	4,660		$	5,466
	Restricted stock			2,604			3,147
	Other			117			77
	Total stock-based compensation expense		$	7,381		$	8,690
	Included in:
	Cost of operations		$	1,389		$	1,464
	Sales and marketing			1,448			2,105
	General and administrative			4,544			5,121
	Total stock-based compensation expense		$	7,381		$	8,690

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Accounting Policies [Abstract]
Reportable operating segments	1

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Revenues from Four Revenue Groups (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Summary of revenues relating to public and private portal
Revenue	$143,343	$133,832
Advertising and Sponsorship [Member]
Summary of revenues relating to public and private portal
Revenue	105,793	102,957
Advertising and Sponsorship [Member] | Biopharma and Medical Device [Member]
Summary of revenues relating to public and private portal
Revenue	75,845	68,488
Advertising and Sponsorship [Member] | OTC, CPG and Other [Member]
Summary of revenues relating to public and private portal
Revenue	29,948	34,469
Private Portal Services [Member]
Summary of revenues relating to public and private portal
Revenue	29,322	24,629
Information Services [Member]
Summary of revenues relating to public and private portal
Revenue	$8,228	$6,246

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Schedule of Net Income Per Common Shares (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Net income - Basic	$10,004	$6,266
Interest expense on 1.50% Notes, net of tax	864
Net income - Diluted	$10,868	$6,266
Denominator:
Weighted-average shares - Basic	36,393	39,268
Stock options and restricted stock	1,378	2,584
1.50% Notes	5,694
Adjusted weighted-average shares after assumed conversions - Diluted	43,465	41,852
Net income per common share:
Basic	$0.27	$0.16
Diluted	$0.25	$0.15

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Schedule of Net Income Per Common Shares (Parenthetical) (Detail)	Mar. 31, 2015
Accounting Policies [Abstract]
Interest on notes	1.50%

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Weighted Average Number of Potentially Dilutive Common Shares Excluded from Computation of Diluted Income Per Common Share (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share	12,884	18,021
Options and Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share	3,168	2,646
1.50% Convertible Notes Due 2020 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share		5,681
2.50% Convertible Notes Due 2018 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share	6,205	6,191
2.25% Convertible Notes Due 2016 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share	3,511	3,503

Convertible_Notes_Additional_I

Convertible Notes - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended					12 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Jan. 11, 2011	Sep. 10, 2014	Sep. 11, 2013	Apr. 04, 2012	Mar. 14, 2011	Dec. 31, 2013	Nov. 26, 2013	Dec. 31, 2014	Sep. 30, 2014
Debt Instrument [Line Items]
Interest on convertible notes	1.50%
Cash paid to repurchase common stock	$3,219	$65,052
2.50% Convertible Notes Due 2018 [Member]
Debt Instrument [Line Items]
Convertible notes due			400,000
Interest on convertible notes			2.50%
Debt instrument, maturity date			31-Jan-18
Proceeds from sale of notes			387,345
Cash paid to repurchase common stock			100,000
Common stock repurchased, shares			1,920,490
Common stock repurchased, price per share			$52.07
Percentage of principal amount equal to repurchase price	100.00%
Principal amount of repurchases remaining	400,000									400,000
2.50% Convertible Notes Due 2018 [Member] | Before Equitable Adjustment [Member]
Debt Instrument [Line Items]
Conversion price per share of common stock			$66.13
Conversion rate of notes per thousand dollar of principal amount			15.122
Common stock available upon conversion			6,048,800
2.50% Convertible Notes Due 2018 [Member] | After Equitable Adjustment [Member]
Debt Instrument [Line Items]
Conversion price per share of common stock				$64.47	$64.61	$65.26
Conversion rate of notes per thousand dollar of principal amount				15.5118	15.4764	15.3223
Common stock available upon conversion				6,204,720	6,190,560	6,128,920
2.25% Convertible Notes Due 2016 [Member]
Debt Instrument [Line Items]
Convertible notes due							400,000
Interest on convertible notes							2.25%
Debt instrument, maturity date							31-Mar-16
Proceeds from sale of notes							387,400
Cash paid to repurchase common stock							50,000
Common stock repurchased, shares							868,507
Common stock repurchased, price per share							$57.57
Common stock available upon conversion								3,503,099
Percentage of principal amount equal to repurchase price											100.00%
Pre-tax loss on repurchase of notes								4,871
Principal amount of repurchases remaining								252,232		252,232
2.25% Convertible Notes Due 2016 [Member] | Before Equitable Adjustment [Member]
Debt Instrument [Line Items]
Conversion price per share of common stock							$73.69
Conversion rate of notes per thousand dollar of principal amount							13.5704
Common stock available upon conversion							5,428,160
2.25% Convertible Notes Due 2016 [Member] | After Equitable Adjustment [Member]
Debt Instrument [Line Items]
Conversion price per share of common stock				$71.84	$72	$72.73
Conversion rate of notes per thousand dollar of principal amount				13.9202	13.8884	13.7502
Common stock available upon conversion				3,511,120	5,555,360	5,500,080
2.25% Convertible Notes Due 2016 [Member] | Privately Negotiated Transaction [Member]
Debt Instrument [Line Items]
Convertible notes repurchased								100,000
Repurchased amount in cash open market								101,750
2.25% Convertible Notes Due 2016 [Member] | Open Market [Member]
Debt Instrument [Line Items]
Convertible notes repurchased								47,768
Repurchased amount in cash open market								48,604
1.50% Senior Convertible Note [Member]
Debt Instrument [Line Items]
Convertible notes due									300,000
Interest on convertible notes									1.50%
Debt instrument, maturity date									1-Dec-20
Proceeds from sale of notes									291,823
Percentage of principal amount equal to repurchase price	100.00%
1.50% Senior Convertible Note [Member] | Before Equitable Adjustment [Member]
Debt Instrument [Line Items]
Conversion price per share of common stock									$52.81
Conversion rate of notes per thousand dollar of principal amount									18.9362
Common stock available upon conversion									5,680,860
1.50% Senior Convertible Note [Member] | After Equitable Adjustment [Member]
Debt Instrument [Line Items]
Conversion price per share of common stock				$52.69
Conversion rate of notes per thousand dollar of principal amount				18.9795
Common stock available upon conversion				5,693,850
1.50% Convertible Notes Due 2020 [Member]
Debt Instrument [Line Items]
Principal amount of repurchases remaining	$300,000									$300,000
Minimum percentage of consideration received or to be received by holders of common stock for repurchase option	90.00%

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Financial Assets Measured and Recorded at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Cash and cash equivalents, Amortized Cost Basis	$735,292	$706,776	$778,401	$824,880
Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Cash and cash equivalents, Amortized Cost Basis	735,292	706,776
Cash and cash equivalents, Fair Value	735,292	706,776
Cash and cash equivalents, Gross Unrealized Gains	0	0
Available-for-sale-security, Amortized cost basis	0	0
Available-for-sale-security, Fair value	1,842	1,603
Available-for-sale-security, Gross unrealized gains	$1,842	$1,603

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Additional Information (Detail) (Private Equity Funds [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Private Equity Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Amount	$6,471
Acquisition costs	$470

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Carrying Value and Estimated Fair Value of Company's Convertible Notes that are Carried at Historical Cost (Detail) (Level 1 [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
2.25% Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Carrying Amount	$252,232	$252,232
Notes, Fair Value	253,493	254,754
2.50% Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Carrying Amount	400,000	400,000
Notes, Fair Value	409,000	399,000
1.50% Senior Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Carrying Amount	300,000	300,000
Notes, Fair Value	$321,000	$299,250

Fair_Value_of_Financial_Instru5

Fair Value of Financial Instruments - Carrying Value and Estimated Fair Value of Company's Convertible Notes that are Carried at Historical Cost (Parenthetical) (Detail)	Mar. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Interest Rate	1.50%
Level 1 [Member] | 2.25% Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Interest Rate	2.25%	2.25%
Level 1 [Member] | 2.50% Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Interest Rate	2.50%	2.50%
Level 1 [Member] | 1.50% Senior Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Interest Rate	1.50%	1.50%

Equity_Additional_Information_

Equity - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Nov. 30, 2014	Apr. 30, 2014	Mar. 31, 2014	Feb. 28, 2014	Oct. 31, 2011	Aug. 31, 2011
Equity, Class of Treasury Stock [Line Items]
Cash paid to repurchase common stock	$3,219	$65,052
2011 Program [Member]
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program authorized additional amount			23,895	30,000	40,000	50,000	75,000
Common stock repurchased, shares	83,504	1,594,904
Cash paid to repurchase common stock	3,219	67,506			2,454
Purchase of treasury stock shares					60,049
Stock repurchase program, remaining authorized repurchase amount	31,792
2011 Program [Member] | Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Funds authorized to repurchase common stock								$75,000

Intangible_Assets_Schedule_of_

Intangible Assets - Schedule of Finite and Indefinite Lived Intangible Assets (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite and finite lived intangible assets, Gross Carrying Amount	$74,887	$74,887
Intangible Assets, Accumulated Amortization	-61,505	-60,672
Indefinite and finite lived intangible assets, Net	13,382	14,215
Content [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Finite lived intangible assets, Gross Carrying Amount	15,954	15,954
Intangible Assets, Accumulated Amortization	-15,954	-15,954
Customer Relationships [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Finite lived intangible assets, Gross Carrying Amount	34,057	34,057
Intangible Assets, Accumulated Amortization	-27,650	-27,126
Finite lived intangible assets, Net	6,407	6,931
Intangible Assets, Weighted Average Remaining Useful Life	3 years 3 months 18 days	3 years 7 months 6 days
Technology and Patents [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Finite lived intangible assets, Gross Carrying Amount	17,882	17,882
Intangible Assets, Accumulated Amortization	-15,498	-15,231
Finite lived intangible assets, Net	2,384	2,651
Intangible Assets, Weighted Average Remaining Useful Life	2 years 3 months 18 days	2 years 6 months
Trade Names-Definitive Lives [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Finite lived intangible assets, Gross Carrying Amount	2,530	2,530
Intangible Assets, Accumulated Amortization	-2,403	-2,361
Finite lived intangible assets, Net	127	169
Intangible Assets, Weighted Average Remaining Useful Life	8 months 12 days	1 year
Trade Names-Indefinite Lives [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, Gross Carrying Amount	4,464	4,464
Indefinite-lived intangible assets, Net	$4,464	$4,464

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Finite-Lived Intangible Assets, Net [Abstract]
Amortization expense	$833	$568

Intangible_Assets_Amortization

Intangible Assets - Amortization Expense for Intangible Assets (Detail) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015 (April 1st to December 31st)	$2,488
2016	3,120
2017	2,044
2018	$1,266

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Dec. 09, 2013	Jun. 27, 2013
Contingencies And Commitments [Line Items]
Outstanding claims		$1,965
Everest Reinsurance Company [Member]
Contingencies And Commitments [Line Items]
Outstanding claims	1,965
Claim filed under stop loss policy	$2,935

StockBased_Compensation_Additi

Stock-Based Compensation - Additional information (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares authorized under 2005 Plan	23,275,000
Common stock available for future grants	354,049
Proceeds from exercise of stock options	$4,488	$17,482
Employee withholding tax paid	1,044	5,326
Combined value of stock options exercised and vested restricted stock	9,135	25,983
Stock-based compensation expense	7,381	8,690
Unrecognized stock-based compensation expense related to unvested awards	81,620
Period for recognition of unrecognized stock based compensation expense	2 years 9 months 18 days
Percentage of tax benefit attributable to stock-based compensation	38.00%	39.00%
Directors [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock-based compensation expense	117	77
Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Expiration period from grant date	10 years
Stock-based compensation expense	$4,660	$5,466
Minimum [Member] | Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share based compensation arrangement by share based payment award, award vesting period	2 years
Maximum [Member] | Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share based compensation arrangement by share based payment award, award vesting period	5 years

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Share-Based Compensation, Stock Options, Activity (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares Outstanding, Beginning Balance	7,547,526
Granted, Shares	1,678,500
Exercised, Shares	-313,663
Cancelled, Shares	-137,075
Shares Outstanding, Ending Balance	8,775,288
Vested and Exercisable, Shares	3,561,862
Weighted Average Exercise Price Per Share, Outstanding, at the beginning of the period	$32.69
Weighted Average Exercise Price Per Share, Granted	$42.52
Weighted Average Exercise Price Per Share, Exercised	$18.44
Weighted Average Exercise Price Per Share, Cancelled	$29.90
Weighted Average Exercise Price Per Share, Outstanding, at the end of the period	$35.12
Weighted Average Exercise Price per Share, Vested and exercisable at the end of the period	$31.08
Weighted Average Remaining Contractual Life (In Years), Outstanding	7 years 3 months 18 days
Weighted Average Remaining Contractual Life (In Years), Vested and exercisable at the end of the period	5 years
Aggregate Intrinsic Value, Outstanding	$81,634
Aggregate Intrinsic Value, Vested and Exercisable	$49,189

StockBased_Compensation_Schedu1

Stock-Based Compensation - Schedule of Share-Based Compensation, Stock Options, Activity (Parenthetical) (Detail) (USD $)	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Market price of common stock	$43.84

StockBased_Compensation_Schedu2

Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Expected volatility, Minimum	46.00%	48.00%
Expected volatility, Maximum	48.00%	49.00%
Risk-free interest rate, Minimum	1.01%	1.28%
Risk-free interest rate, Maximum	1.56%	1.71%
Weighted-average fair value of options granted during the period	$16.34	$17.47
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	4 years 1 month 6 days	4 years 3 months 18 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	4 years 8 months 12 days	4 years 10 months 24 days

StockBased_Compensation_Schedu3

Stock-Based Compensation - Schedule of Share-based Compensation, Restricted Stock Awards, Activity (Detail) (Restricted Stock [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Stock Awards, Shares, Balance at the beginning of the year	904,083
Restricted Stock Awards, Shares, Granted	355,920
Restricted Stock Awards, Shares, Vested	-34,216
Restricted Stock Awards, Shares, Forfeited	-25,000
Restricted Stock Awards, Shares, Balance at the end of the year	1,200,787
Weighted Average Grant Date Fair Value, Balance at the beginning of the year	$35.58
Weighted Average Grant Date Fair Value, Granted	$42.75
Weighted Average Grant Date Fair Value, Vested	$46.43
Weighted Average Grant Date Fair Value, Forfeited	$26.22
Weighted Average Grant Date Fair Value, Ending Balance	$37.60

StockBased_Compensation_Schedu4

Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$7,381	$8,690
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	4,660	5,466
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,604	3,147
Other [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	117	77
Cost of Operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1,389	1,464
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1,448	2,105
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$4,544	$5,121